Toshihide Yamashita Editor

Dr. Mohamed is a clinical pharmacologist, neuroscientist, and psychiatrist. Dr. Mohamed got his PhD from PSU, USA, and is currently working as an assistant professor in IIUM Medical School, Malaysia. Dr. Mohamed has been invited to deliver more than 120 lectures locally and abroad. He has published over 60 peer-reviewed papers related to neuroscience/psychiatry with an h-index of 16. Moreover, he is an editor in Frontiers in Neurology and PLOS-ONE journal, and has edited many journal special issues on brain disorders. Additionally, he is editing a few books in the field of neuroscience with Springer and Cambridge. He has received many research grants from national and international organizations, namely IBRO, ISN, MJF, STDF, FRGS, and INDO-ASEAN, with a total research funding of half a million US dollars. He is now an active partner in GP2 consortium (IPDG-Asia).

Toshihide Yamashita is the Osaka University Distinguished Professor and the head of the Department of Molecular Neuroscience and the Department of Neuro-Medical Science, Graduate School of Medicine, Osaka University. He graduated from Osaka University Medical School in 1990 and had clinical training as a neurosurgeon. His research has focused on restoration and regeneration of the injured or degenerated central nervous system (CNS). In 2005, he received Ameritec Prize (USA), which was awarded in recognition of a specific, significant accomplishment in medical research toward functional recovery from spinal cord injury. The Japan Society for the Promotion of Sciences (JSPS) Prize (2011), Osaka Science Prize (2012), and Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology (2014) were awarded to him for his discovery of molecular mechanisms regulating the regeneration and plasticity of injured CNS. He has published more than two hundred international original research papers. He is now developing humanized antibody that targets one of the axon growth inhibitors in collaboration with Mitsubishi Tanabe Pharma, and is carrying out the clinical trial for spinal cord injury.